SARA-31: A phase 3 trial to evaluate the efficacy and safety of BIO-101 in elderly patients suffering from severe SARcopeniA: an interventional, randomized double-blind placebo- controlled, clinical trial.
The SARA-31 study is a major research effort focused on a condition called sarcopenia, where older people lose muscle strength, making everyday movements difficult. We're testing a new medicine called BIO-101 to see if it can help. In this study, some participants will receive BIO-101, while others will get a 'dummy pill' (placebo), neither they nor their doctors will know which. We want to find out if BIO-101 can slow down or prevent serious problems with moving around caused by sarcopenia. Researchers will also look at how BIO-101 affects walking speed, hand strength, and overall quality of life. This is a crucial step to understand if BIO-101 is a safe and effective treatment for sarcopenia.
At a glance
What is this study about?
Sarcopenia is a common condition that affects many older people. It means you gradually lose muscle mass and strength, making it harder to do everyday activities like walking, climbing stairs, or even getting up from a chair. Over time, this can lead to serious problems with mobility, which means struggling to move around independently.
This study, called SARA-31, is designed to see if a new medication, BIO-101, can make a difference for people living with severe sarcopenia. The main goal is to find out if BIO-101 can help delay or even prevent these serious mobility problems. We're also interested in whether it improves specific things like how fast you can walk, how strong your grip is, and how sarcopenia affects your overall quality of life.
To get a clear answer, the study compares BIO-101 to a 'placebo.' A placebo looks just like the real medicine but contains no active ingredients. This helps researchers understand if any improvements are truly due to BIO-101 or if they might happen anyway. Neither you nor your study doctor will know whether you're receiving BIO-101 or the placebo, which helps make the study fair and unbiased. This type of study is a big step in determining if BIO-101 could become a new treatment option for sarcopenia.
Key takeaways
- SARA-31 is testing a new medicine, BIO-101, for severe sarcopenia.
- The study aims to prevent serious mobility problems.
- It's a 'blinded' study, so you might get a dummy pill.
- Participation involves regular clinic visits and assessments for about a year.
- You can stop participating at any time.
- This study is a key step towards finding new treatments for sarcopenia.
Who may be eligible?
This study is open to both men and women. We are looking for older adults who have been diagnosed with severe sarcopenia.
There are no specific age limits mentioned, meaning that if you are an adult with severe sarcopenia, you might be able to participate. The study team will check your full medical history to make sure taking part is safe and appropriate for you.
It's important to discuss with your doctor if you think you might be eligible, as they can help determine if this study is a good match for your health situation.
Could this study suit you?
Answer these quick questions to see if you may be eligible. This is a guide only — the research team makes the final call.
- Are you an older adult?
- Do you have a diagnosis of severe sarcopenia?
- Are you willing to take a study medication, which might be a dummy pill?
- Are you able to attend regular clinic visits for about one year?
What does participation involve?
If you decide to take part in this study, you would receive either the study medication, BIO-101, or a dummy pill (placebo) in capsule form. You would take these capsules regularly as instructed by the study team. Over the course of approximately one year (52 weeks), you would have several visits to the clinic.
During these visits, the study team would monitor your health and progress. This would involve various assessments, such as checking your walking speed over a short distance, measuring your handgrip strength, and asking you to fill out questionnaires about how sarcopenia affects your daily life. They will also keep an eye on your general health and any side effects you might experience. The total duration of your active participation in the study is planned for 52 weeks.
Potential risks and benefits
Locations (1)
- —UnverifiedBelgium
Common questions
What is sarcopenia?
Sarcopenia is a condition where people, usually as they get older, lose muscle mass and strength, making it harder to move around and do daily activities.
What is BIO-101?
BIO-101 is the new medication being tested in this study to see if it can help improve muscle strength and mobility in people with severe sarcopenia.
What does 'double-blind' mean?
It means that neither you nor your study doctor will know if you are receiving the active medicine (BIO-101) or a dummy pill (placebo). This helps make the study results fair.
What is a 'placebo'?
A placebo is a 'dummy pill' that looks exactly like the study medication but contains no active ingredients. It's used to compare against the real medicine.
How long will I be in the study?
Your active participation in the study, including taking the medication and having regular check-ups, is planned for about 52 weeks, which is roughly one year.
How to find out more
Always speak to your GP or specialist before deciding to take part in a study.
Discussion
Community discussion
Powered by our forum at community.patient.info. Please be respectful — this is not medical advice.